|Bid||35.08 x 1400|
|Ask||35.45 x 800|
|Day's Range||34.65 - 36.94|
|52 Week Range||26.00 - 65.48|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.67|
REDWOOD CITY, Calif., Feb. 19, 2019 -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases,.
-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by.
Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19th starting at 12:00 pm ET in New York City. The event will feature an overview of the AK002 development program, including a presentation of the chronic urticaria and indolent systemic mastocytosis (ISM) clinical results to date by Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité University in Berlin, a noted expert in the field of urticaria, indolent systemic mastocytosis, and other allergic conditions.
Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results from two additional chronic urticaria cohorts: patients with cholinergic urticaria and symptomatic dermographism (also referred to as dermatographic urticaria). Earlier this month, Allakos reported that 12 of 13 patients (92%) in the Xolair-naïve chronic spontaneous urticaria (CSU) cohort achieved a complete response with AK002. Top-line results for the remaining urticaria cohort, patients with chronic spontaneous urticaria who failed to respond to Xolair, are expected later in the first quarter of 2019.
Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive top-line results for the Xolair-naïve chronic spontaneous urticaria (CSU) cohort from its Phase 2 study. The principle investigator is Dr. Marcus Maurer, MD, Professor of Dermatology and Allergy at Charité University in Berlin. The Xolair-naïve chronic spontaneous urticaria cohort enrolled 13 patients with uncontrolled urticaria despite treatment with H1 antihistamines at doses of up to 4 times the labeled dosage.
Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.
Some 81% of the companies that went public in 2018 priced in or above their indicated range—the most in over a decade, according to Renaissance Capital, a manager of IPO exchange-traded funds. The 2018 class of initial public offerings has now returned minus 2.3% this year, versus the five-year average return of 20%. In total, 190 companies—almost 20% more than 2017 and the most since 2014—went public, Renaissance Capital says.
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
Stocks with market capitalization between $2B and $10B, such as Allakos Inc (NASDAQ:ALLK) with a size of US$2.3b, do not attract as much attention from the investing community as do Read More...
Allakos Inc (NASDAQ: ALLK ), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO at $18 per share. The Analysts ...